Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma; Ocular Hypertension
Intervention: Brimonidine ophthalmic solution 0.1% (Drug); Brimonidine ophthalmic solution 0.2% (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan
Summary
This study evaluates the safety and efficacy of brimonidine 0. 1% ophthalmic solution
compared with brimonidine 0. 2% ophthalmic solution in patients with glaucoma or ocular
hypertension
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Intraocular pressure (IOP)
Secondary outcome: IOP
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Ocular hypertension or glaucoma in both eyes
Exclusion Criteria:
- Uncontrolled systemic disease
- Known allergy or sensitivity to brimonidine
Locations and Contacts
Atlanta, Georgia, United States
Additional Information
Link to Clinical Trial Results
Starting date: May 2003
Last updated: April 1, 2008
|
